A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001

NCT06852963 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Retinitis Pigmentosa 11
Retinal Degeneration
Retinal Disease
Eye Diseases Hereditary
Retinal Dystrophies

Interventions

DRUG: VP-001

Sponsor

PYC Therapeutics